Israel warns Lebanon of ‘heavy price’ as bombardment pounds Beirut suburbs: Reuters
Lebanon was dragged into the wider Middle East war on Monday when Hezbollah fired at Israel, which responded with a new military campaign.
Iran vows it won’t surrender as war with the U.S. and Israel enters second week
The U.S. and Israel continued their campaign to rid Tehran of its nuclear and ballistic missile capabilities and push for regime change.
Palantir rallies 15% for the week as Iran war boosts prospects, muting Anthropic concern
Palantir’s stock had its best week since August and outperformed all of its large-cap tech peers after the U.S. attacked Iran.
Amazon says Anthropic’s Claude still OK for AWS customers to use outside defense work
Amazon joined Microsoft and Google in continue to offer Anthropic’s Claude AI technology to customers after the Pentagon deemed it a “supply chain risk.”
Google joins Microsoft in telling users Anthropic is still available outside defense projects
Cloud vendors are letting customers know that Anthropic’s popular AI tools can still be accessed after the Department of Defense blacklisted the company.
Trump admin announces $20 billion reinsurance program for oil tankers during Iran war
Tanker traffic through the Strait of Hormuz remains at a standstill as the Iran war engulfs the region.
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
Pharmaceutical stocks like Eli Lilly and Merck are good places to help investors ride out a recent rise in geopolitical turmoil, according to UBS.
Stocks making the biggest moves midday: Marvell Technology, BlackRock, United Airlines, CF Industries & more
These are the stocks posting the largest moves in midday trading.
Marvell stock surges 18% as CEO points to continuing AI demand: ‘Do you see me blinking?’
Marvell shares surged on Friday after the company beat earnings expectations and issued strong guidance on continuing AI demand.
Zealand’s stock plummets after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.
